Conjupro Biotherapeutics, Inc.
Clinical trials sponsored by Conjupro Biotherapeutics, Inc., explained in plain language.
-
New drug CPO-100 tested in patients with advanced cancers
Disease control TerminatedThis early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New lymphoma drug trial ends early after just 7 patients
Disease control TerminatedThis early-stage study tested a new drug called CPO107 in people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find the safest dose and check for side effects. Only 7 people took part before the study was stopped early.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:01 UTC